2014华中科技大学博士一年级英语考试参考样体

Key to 09 Model Test

I. Read the following and answer the questions. (10%)

2007 JCR Science Edition

Journals from:

subject categories MEDICINE, GENERAL & INTERNAL

Sorted by:

Impact Factor

Journals 1 - 20 (of 100)

[ 1 | | | | ]

Page 1 of 5

Ranking is based on your journal and sort selections.

Abbreviated Journal

Rank

Title

(linked to journal information)

ISSN

Total Impact Immediacy Cites

Factor

Index

Articles

Cited Half-life

1 2 3 4 5 6 7 8 9 10

0028-4793 186402 52.589 0140-6736 135949 28.638

11.962 8.636 7.965 4.056 2.879 2.705 6.210 1.734 3.053 0.593

343 305 229 162 33 166 210 278 94 54

7.0 7.7 6.8 8.6 6.1 1.9 8.2 7.2 6.4 6.1

0098-7484 103620 25.547

0003-4819 40783 15.516 0066-4219 1549-1277

3829 13.415 3725 12.601

9.723 8.391 7.067 5.779

0959-8146 62151 0003-9926 30282 0820-3946 0785-3890

8324 3143

1. What is the option of this journal citation report?

2007 JCR Science Edition

2. What is the subject category?

MEDICINE, GENERAL & INTERNAL

3. How is the list sorted? By Impact Factor

4. What is the Impact Factor of New England Journal of Medicine?

52.589

5. What is the full title of BRIT MED J? British Medical Journal

II. Read the following and answer the questions. (10%)

Web of Science

Results

Subject Heading=(LIFE SCIENCES BIOMEDICINE) AND Author=(WANG SY) AND Institution=(HUAZHONG UNIV SCI TECHNOL)

Timespan=All Years. Databases=IC, SCI-EXPANDED, CCR-EXPANDED [back to 1840], SSCI.

1. Zhang ZH, Wang SY, Li Q, et al.

LANCET 366 (9485): 556-562 AUG 13 2005

Times Cited: 0

2. Zhang SH, Wang SY, Yao SL

ANESTHESIOLOGY 100 (6): 1387-1393 JUN 2004

Times Cited:

3. Zhang SH, Wang SY, Yao SL

ACTA PHARMACOLOGICA SINICA 25 (3): 334-340 MAR 2004

Times Cited:

6. What is the website you can use to find the SCI collection? Web of Science

7. What is the subject heading? LIFE SCIENCES BIOMEDICINE

8. Where is Wang SY from?

HUAZHONG UNIV SCI TECHNOL

9. How many articles of Wang SY are collected by SCI? 3

10. How many times are his articles cited? 8

III. Read the following and answer the questions. (20%)

J. Biol. Chem., Vol. 278, Issue 18, 15541-15549, May 2, 2003

Induction of Prothrombinase fgl2 by the Nucleocapsid Protein of Virulent Mouse Hepatitis Virus Is Dependent on Host Hepatic Nuclear Factor-4

Qin Ning, Sophia Lakatoo, Mingfeng Liu, Weiming Yang, Zhimo Wang, M. James Phillips, and Gary A. Levy

Fibrinogen-like protein 2/fibroleukin (Fgl2) plays a pivotal role in the pathogenesis of both experimental and human fulminant hepatic failure. We have reported recently that the nucleocapsid (N) protein from strains of murine hepatitis virus (MHV-3, MHV-A59), which cause massive hepatocellular necrosis but not from strains (MHV-JHM, MHV-2) which do not produce serious liver disease, induces transcription of fgl2. The purpose of the present study was to characterize both viral and host factor(s) necessary for viral induced transcription of fgl2. Mutation of residues Gly-12, Pro-38, Asn-40, Gln-41, and Asn-42 within domain 1 of the N protein of MHV-A59 to their corresponding residues found in MHV-2 abrogated fgl2 transcription, whereas mutation of other N protein domains, including a protein expressed from an internal reading frame (I protein), did not affect fgl2 gene transcription. We then examined the 372 to 306 sequence within the 1.3-kb fgl2 promoter region upstream from the transcription start site that was previously identified as necessary for N protein-induced gene transcription. We demonstrated that the 331/325 HNF4 cis-element and its cognate transcription factor, HNF4, are necessary for virus-induced fgl2 gene transcription. In uninfected macrophages and macrophages infected with MHV-2, an unidentified protein occupies the HNF4 cis-element. Following stimulation with MHV-A59, it was shown by electrophoretic mobility shift assay that HNF4 binds the HNF4 cis-element in the fgl2 promoter. We further report the unprecedented presence of HNF4 in peritoneal macrophages. Collectively, the results of this study define both viral and host factors necessary for induction of fgl2 prothrombinase gene transcription in MHV infection and may provide an explanation for the hepatotrophic nature of MHV-induced fulminant hepatic failure.

11. How many parts can you divide the abstract into? 4

12. Name each part? Background/Purpose Method Results Conclusion

13. Which sentence is the purpose of the study?

The purpose of the present study was to characterize both viral and host factor(s) necessary for viral induced transcription of fgl2.

14. Which sentence is the conclusion?

Collectively, the results of this study define both viral and host factors necessary for induction of fgl2 prothrombinase gene transcription in MHV infection and may provide an explanation for the hepatotrophic nature of MHV-induced fulminant hepatic failure./The last sentence

IV . Read the following and answer the questions. (20%)

Acta Pharmacologica Sinica 2005 Jul; 26 (7): 873–880

Full-length article

Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt’s lymphoma Daudi cells in vitro1

Hong-li LIU, Yan CHEN2, Guo-hui CUI, Qiu-ling WU, Jing HE

Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Introduction

A large number of natural products have been evaluated as potential chemopreventive agents. Deguelin (Figure 1), a natural plant-derived rotenoid, most commonly used as an insecticide in Africa and South America, has been isolated from several plant species, including Mundulea sericea (Leguminosae ). Its main active composition is rotenone, and it has very strong photodissociation[1]. The recent research has indicated that deguelin usually has a very strong antitumor function, and can suppress many kinds of tumors cell at nmol levels[1]. Notably, deguelin can suppress coloncancer cell HT-29 growth[2], inhibit the growth of precancerous and cancerous lung cells, and induce premalignant and malignant human bronchial epithelial (HBE) cells apoptosis with no toxic effects on normal cells[3]. These recent experiments verified that deguelin could lead the cell cycle to block and induce apoptosis, however, its mechanism is not yet completely clear.

Burkitt’s lymphoma (also called small noncleaved cell lymphoma) is a type of on-Hodgkin’s lymphoma, a cancer in the lymphatic system. Despite recent advances in radiotherapy,

chemotherapy, and stem cell transplant, the severe morbidity from lymphoma has not been improved[4]. Much effort has been focused on the discovery and development of new chemopreventive agents, especially agents targeted at mechanisms known to be involved in the process of carcinogenesis. Therefore, we have sought to identify novel agents that can prevent lymphoma carcinogenesis effectively but with minimal toxicity.

This study was designed to explore the mechanism of deguelin-induced apoptosis in Daudi cells. We studied deguelin on human Burkitt’s lymphoma Daudi cells in vitro and compared the cytotoxicities of deguelin on Daudi cells with human peripheral blood monocular cell (PBMC), and focused on the changes in the expression of cyclin D1 and phosphor-Rb, and analyzed its underlying mechanism.

15. How many parts can you divide the introduction into? 4

16. Name each part? Background Conclusion Purpose Method

17. Which sentence is the purpose of the study?

This study was designed to explore the mechanism of deguelin-induced apoptosis in Daudi cells.

18. Which sentence is the conclusion?

Therefore, we have sought to identify novel agents that can prevent lymphoma carcinogenesis effectively but with minimal toxicity.

V . Read the following and answer the questions. (20%) References and Notes

1. State Council AIDS Working Committee Office, U.N. Theme Group on HIV/AIDS in China, A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (Beijing, 2004). 2. J. Watts, Lancet 362, 1983 (2003).

3. Ministry of Health of China, UNAIDS, and WHO, 2005 Update on the HIV/AIDS Epidemic and Response in China [Chinese Center for Disease Control and Prevention (China CDC), Beijing, 2006].

4. M. J. Rotheram-Borus, P. A. Newman, M. A. Etzel, J. Acquir. Immune Defic. Syndr. 25 (suppl. 2), S105 (2000).

5. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group, Lancet 356, 103 (2000). 6. S. Allen et al., AIDS 17, 733 (2003).

7. H. Amaro, A. C. Morrill, J. Dai, J. Health Psychol. 10, 287(2005). 8. M. E. Bentley et al., AIDS 12, 1869 (1998).

9. R. Fox, N. J. Odaka, R. Brookmeyer, B. R. Polk, AIDS 1, 241 (1987).

10. J. A. Inciardi, H. L. Surratt, S. P. Kurtz, J. C. Weaver, AIDS Care 17 (suppl. 1), S88 (2005). 11. R. R. Robles, T. D. Matos, H. M. Colon, C. A. Marrero, J. C. Reyes, Drugs Soc. (New York) 9, 173 (1996).

12. A. Erikson et al., Correspondent 15, 24 (2006).

13.T. Frieden et al., N. Engl. J. Med. 353, 2397-2402 (2005). 14. R. Bayer, N. Engl. J. Med. 334, 1540 (1996).

15. L. B. Leveton, H. C. Sox, M. A. Stoto, Eds. HIV and the Blood Supply: An Analysis of Crisis Decision-Making (Institute of Medicine, National Academies Press, Washington, DC, 1995). 16. Chinese Ministry of Health, U.N. Theme Group on HIV/AIDS in China, The Third

Conference on HIV/AIDS International Cooperation Projects in China, Kunming, 3 to 4 September 2005.

17. UNAIDS-WHO, "Policy statement on HIV testing"

(www.who.int/entity/rpc/research_ethics/hivtestingpolicy_en_pdf.pdf).

18. Ministry of Health Expert Consultation Committee, "Report on HIV screening among key

populations in Henan province" (Ministry of Health, Beijing, 2005).

19. Ministry of Health Expert Consultation Committee, "Report on HIV screening among key

populations in Yunnan Province" (Ministry of Health, Beijing, 2005).

20. HIV-positive mothers are given the options of abortion or ART perinatally, cesarean delivery (where available), and free formula milk for 12 months.

21. State Council Regulations on AIDS Prevention and Treatment, Articles 3, 10, 39, 41, 55, 56. 22. The Infectious Diseases Control Act of the People's Republic of China, Articles 12, 16, 68, 69.

We thank S. Korenman, Associate Dean for Ethics at the UCLA School of Medicine, for reviewing this manuscript, W. W. Cao for review of relevant publications, and W. Aft for editorial assistance.

19. What kind of the reference source does the first reference belong to? Technical report

20. What kind of the reference source does the second reference belong to? Journal

21. What kind of the reference source does Reference 15 belong to? Book

22. What kind of the reference source does Item 20 belong to? Note

VI. Read the following and answer the questions. (10%)

SCI Impact Factor 1.677

Acta Pharmacologica Sinica Information For Authors

GENERAL

1 Acta Pharmacologica Sinica, published monthly in English, is the official journal of the Chinese

Pharmacological Society and Shanghai Institute of Materia Medica, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences. Acta Pharmacologica Sinica is listed in Biological Abstracts, Chemical Abstracts, CSA Medical Biotechnology, CSA Bioengineering, CSA Neuroscience, Current Contents/Life Sciences, Excerpta Medica, FSTA, Global Health, IndexCopernicus, Index Medicus, Kagaku Gijutsu Bunken Sokuho, MEDLINE, Рефератнвныйжурнап, Research Alert, Science Citation Index, SciSearch, Scopus, Tropical Diseases Bulletin, and many other abstracting and indexing services.

Acta Pharmacologica Sinica welcomes current Original articles on all aspects of the life sciences and related areas, both experimental and clinical, from any part of the world. Reviews based primarily on authors?own research of internationally important topics are also welcome.

Manuscripts should be prepared in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication" as presented at .

2 Prior or duplicate publications are not accepted. All manuscripts, especially data, must not be published or submitted for publication elsewhere. English translations of published articles are not acceptable. The authors should make a full statement on submission about all submissions and previous reports that might be regarded as redundant or duplicate publications of the same or very similar work.

The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. …

23. What is the SCI Impact Factor of Acta Pharmacological Sinica? SCI Impact Factor 1.677

24. What kinds of original article are welcomed by Acta Pharmacological Sinica?

current Original articles on all aspects of the life sciences and related areas, both experimental and clinical, from any part of the world.

25. What is the website presenting the "Uniform Requirements for Manuscripts Submitted to

Biomedical Journals: Writing and Editing for Biomedical Publication"? .

26. Does Acta Pharmacological Sinica accept English translations of published articles? No

27. What must be acknowledged if an article is accepted to be published in Acta Pharmacological

Sinica?

The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors' industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged.

VI. Read the following and answer the questions. (10%)

United States

National Library of Medicine National Institutes of Health

Grants and Funding: Extramural Programs

Research Project Grants (NIH Parent R01) (PA 07-070)

Purpose

Support for rigorous scientific research in biomedical informatics and bioinformatics. Investigators applying through this NIH Parent R01 announcement should include a cover letter requesting assignment to NLM. The NIH parent announcement does not contain information about NLM's research grant priorities and scope of interest. For NLM-specific guidance, see .

This program expires January 8, 2010 unless reissued. Only electronic applications are accepted.

NLM Contacts

Clinical and Public Health Informatics: Dr. Hua-Chuan Sim,

Bioinformatics and Computational Biology: Dr. Jane Ye,

Deadlines

Deadlines for New Applications: February 5, June 5 and October 5 each year

Deadlines for Revised Applications: March 5, July 5 and November 5 each year

Full listing of deadlines for competing applications:

Last reviewed: 28 February 2008 Last updated: 28 February 2008 First published: 05 February 2008

28. What is this webpage about?

Research Project Grants (NIH Parent R01) (PA 07-070)

29. What is the purpose of this grant?

Support for rigorous scientific research in biomedical informatics and bioinformatics.

30. When will this program expire?

January 8, 2010 unless reissued

31. If you are a potential applicant, who will you contact about the suitability of a project for

funding by NLM?

Dr. Hua-Chuan Sim or Dr. Jane Ye

32. How many deadlines are there for New Applications each year? 3